Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial

Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial

Abstract Background For patients with steroid-refractory acute graft-versus-host disease (SR-aGVHD), effective second-line regimens are urgently needed. Mesenchymal stromal cells (MSCs) have been used as salvage regimens for SR-aGVHD in the past. However, clinical trials and an overall understanding...

Full description

Bibliographic Details
Main Authors: Haixia Fu, Xueyan Sun, Ren Lin, Yu Wang, Li Xuan, Han Yao, Yuanyuan Zhang, Xiaodong Mo, Meng lv, Fengmei Zheng, Jun Kong, Fengrong Wang, Chenhua Yan, Tingting Han, Huan Chen, Yao Chen, Feifei Tang, Yuqian Sun, Yuhong Chen, Lanping Xu, Kaiyan Liu, Xi Zhang, Qifa Liu, Xiaojun Huang, Xiaohui Zhang
Format: Article
Language:English
Published: BMC 2024-02-01
Series:BMC Medicine
Subjects:
Mesenchymal stromal cells
Haemopoietic stem cell transplantation
Haploidentical
Acute graft-versus-host disease
Steroid-refractory
Second-line therapy
Online Access:https://doi.org/10.1186/s12916-024-03275-5

Internet

https://doi.org/10.1186/s12916-024-03275-5

Similar Items